A comprehensive view of Genmab A/S. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Tissue & Hygiene Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AI and precision medicine firm Tempus names Kate Sasser, PhD, as Chief Scientific Officer to bring personalized medicine solutions to market; Dr. Sasser previously served at biotech firm Genmab

Genmab announces net sales of DARZALEX daratumumab for Q3 totaled US$2.1B; US sales totaled US$1.1B of the injectable cancer drug

Genmab announces Q2 net profit up at 1.9B Danish krone from 306.0M Danish krone a year ago, with revenue up at 3.2B Danish krone from 1.97B Danish krone a year ago; results driven by higher royalties for injectables Darzalex, Tepezza, Kesimpta

Genmab reports Q2 global net sales of injectable and intravenous Darzalex of US$2.0M, with net US sales of US$1.0M; Janssen holds exclusive worldwide license to develop, manufacture, sell Darzalex and provides Genmab with royalties on sales

Genmab reports Q1 global net sales of injectable Darzalex at US$1.9B, with net US sales at US$953M, net sales in other parts of the world at US$903M; drug is first FDA-approved monoclonal antibody to treat multiple myeloma

Ask us about our Tissue & Hygiene market view

Trending Chart

Interactive chart with headline count